Abstract
Objectives: A considerable number of patients do not achieve an adequate response to clopidogrel. Our study aimed to evaluate genetic and non-genetic factors as possible risks for clopidogrel high on-treatment platelet reactivity (HTPR) in patients (n=112) with carotid artery stenosis undergoing endarterectomy (CEA).
Methods: Using multiple-electrode impedance aggregometry (MEA) the antiplatelet effectiveness of clopidogrel was measured after 24 h, 7 and 30 days of clopidogrel treatment, which was introduced after elective CEA at a dose of 75 mg daily, for at least 30 days.
Results: HTPR was observed among 25% patients after clopidogrel therapy for 30 days. Further analysis showed that 53.3% of patients carrying the CYP2C19*2 gene variant had clopidogrel-HTPR, while in the wild type group there were 14.6% (p<0.001). Multivariate logistic regression analysis identified the CYP2C19*2 variant allele (OR 4.384; 95% CI 1.296-14.833, p=0.017) and high total cholesterol level (OR 2.090; 95% CI 1.263-3.459, p=0.004) as the only independent risk factors for clopidogrel-HTPR.
Conclusion: The CYP2C19*2 gene variant and high total cholesterol level were major factors for clopidogrel- HTPR in patients with carotid artery stenosis undergoing CEA.
Keywords: Carotid artery stenosis, carotid endarterectomy, clopidogrel, platelet reactivity, risk factors, CYP2C19*2.
Current Vascular Pharmacology
Title:Clopidogrel High On-Treatment Platelet Reactivity in Patients with Carotid Artery Stenosis Undergoing Endarterectomy. A Pilot Study
Volume: 14 Issue: 6
Author(s): Dragana Backovic, Svetlana Ignjatovic, Ljiljana Rakicevic, Mirjana Novkovic, Jelena Kusic-Tisma, Dragica Radojkovic, Evgenija Strugarevic, Branko Calija, Djordje Radak and Mirjana Kovac
Affiliation:
Keywords: Carotid artery stenosis, carotid endarterectomy, clopidogrel, platelet reactivity, risk factors, CYP2C19*2.
Abstract: Objectives: A considerable number of patients do not achieve an adequate response to clopidogrel. Our study aimed to evaluate genetic and non-genetic factors as possible risks for clopidogrel high on-treatment platelet reactivity (HTPR) in patients (n=112) with carotid artery stenosis undergoing endarterectomy (CEA).
Methods: Using multiple-electrode impedance aggregometry (MEA) the antiplatelet effectiveness of clopidogrel was measured after 24 h, 7 and 30 days of clopidogrel treatment, which was introduced after elective CEA at a dose of 75 mg daily, for at least 30 days.
Results: HTPR was observed among 25% patients after clopidogrel therapy for 30 days. Further analysis showed that 53.3% of patients carrying the CYP2C19*2 gene variant had clopidogrel-HTPR, while in the wild type group there were 14.6% (p<0.001). Multivariate logistic regression analysis identified the CYP2C19*2 variant allele (OR 4.384; 95% CI 1.296-14.833, p=0.017) and high total cholesterol level (OR 2.090; 95% CI 1.263-3.459, p=0.004) as the only independent risk factors for clopidogrel-HTPR.
Conclusion: The CYP2C19*2 gene variant and high total cholesterol level were major factors for clopidogrel- HTPR in patients with carotid artery stenosis undergoing CEA.
Export Options
About this article
Cite this article as:
Backovic Dragana, Ignjatovic Svetlana, Rakicevic Ljiljana, Novkovic Mirjana, Kusic-Tisma Jelena, Radojkovic Dragica, Strugarevic Evgenija, Calija Branko, Radak Djordje and Kovac Mirjana, Clopidogrel High On-Treatment Platelet Reactivity in Patients with Carotid Artery Stenosis Undergoing Endarterectomy. A Pilot Study, Current Vascular Pharmacology 2016; 14 (6) . https://dx.doi.org/10.2174/1570161114666160714103148
DOI https://dx.doi.org/10.2174/1570161114666160714103148 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Developments in Thrombin-Activatable Fibrinolysis Inhibitor Research
Mini-Reviews in Medicinal Chemistry Selective Divalent Copper Chelation for the Treatment of Diabetes Mellitus
Current Medicinal Chemistry Vitamin D in Atherosclerosis, Vascular Disease, and Endothelial Function
Current Drug Targets Cellular Mechanisms of the Protective Effect of Polyphenols on the Neurovascular Unit in Strokes
Cardiovascular & Hematological Agents in Medicinal Chemistry Potential Roles of MyomiRs in Cardiac Development and Related Diseases
Current Cardiology Reviews Sodium Intake, Circulating Microvesicles and Cardiovascular Outcomes in Type 2 Diabetes
Current Diabetes Reviews Lessons from the REACH Registry in Europe
Current Vascular Pharmacology The Impact of Natural Compounds on the Treatment of Neurodegenerative Diseases
Current Organic Chemistry Pharmacogenetic Modulation of Platelet Inhibition
Current Pharmacogenomics and Personalized Medicine Monitoring Calcific Aortic Valve Disease: The Role of Biomarkers
Current Medicinal Chemistry Effects of Carotenoids on Health: Are All the Same? Results from Clinical Trials
Current Pharmaceutical Design Glycation and Hypoxia: Two Key Factors for Adipose Tissue Dysfunction
Current Medicinal Chemistry Cholesterol and Alzheimers Disease: Clinical and Experimental Models Suggest Interactions of Different Genetic, Dietary and Environmental Risk Factors
Current Drug Targets Novel Coronavirus SARS-CoV-2 (COVID-19) and Pregnancy: A Hypothetical View
Endocrine, Metabolic & Immune Disorders - Drug Targets The Diabetic Charcot Foot
Current Diabetes Reviews Choosing a Revascularization Strategy in Patients with Diabetes and Stable Coronary Artery Disease: A Complex Decision
Current Cardiology Reviews Virus-Associated Vasculitides
Current Immunology Reviews (Discontinued) Multiple Roles of Fibroblast Growth Factor 21 in Metabolism
Current Pharmaceutical Design Nutraceutical: A Drug, Dietary Supplement and Food Ingredient
Current Pharmacogenomics and Personalized Medicine Role of Oxidative Stress in the Development of Vascular Injury and its Therapeutic Intervention by Nifedipine
Current Medicinal Chemistry